



[Web Publication Date: 5/4/2009](#)

Chemical Name: Benzene
CAS: 71-43-2

Acute Non-Cancer Health Risk Limit (nHRL_{acute}) = 10 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Acute intake rate, L/kg/d})}$$

$$= \frac{(0.015 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.289 \text{ L/kg-d})}$$

$$= 10.38 \text{ rounded to } \mathbf{10 \text{ µg/L}}$$

Toxicity value:	0.015 mg/kg/day (laboratory animal)
Source of toxicity value:	MDH 2007
Point of Departure:	4.6 mg/kg/day (NOAEL from Coate et al 1984)
Human Equivalent Dose Adjustment:	Not available
Total uncertainty factor:	300
UF allocation:	10 (intraspecies variability), 10 (interspecies extrapolation) and 3 database insufficiencies (sensitive endpoints, such as hematological, immunological and neurological effects, have not been adequately evaluated in developmental studies)
Critical effect(s):	Reduced fetal body weight, increased skeletal variants, and slight dilation of brain ventricles.
Co-critical effect(s):	[A limited number of developmental inhalation and injection studies suggested increased sensitivity to hematological and neurological effects. These studies were not always consistent and suffered from deficiencies in design. Therefore, these endpoints have not been listed as co-critical effects at this time. However, a database UF has been applied to address these concerns.]
Additivity endpoint(s):	Developmental (BW, skeletal)
Secondary effect(s):	None

Short-term Non-Cancer Health Risk Limit (nHRL_{short-term}) = 10 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Short-term intake rate, L/kg/d})}$$

$$= \frac{(0.014 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.289 \text{ L/kg-d})}$$

$$= 9.68 \text{ rounded to } \mathbf{10 \text{ µg/L}}$$

Toxicity value:	0.014 mg/kg/day (laboratory animal)
Source of toxicity value:	MDH 2007
Point of Departure:	1.4 mg/kg/day (IRIS BMDL based on Hsieh et al., 1988a)
Human Equivalent Dose Adjustment:	Not available
Total uncertainty factor:	100
UF allocation:	10 (intraspecies variability), 10 (interspecies extrapolation)
Critical effect(s):	Reduced blood cell counts, increased MCV, increased anemia, decreased spleen weight, elevated splenic lymphocytes, H-TdR, Con A, PHA-induced response, CTL responsiveness, PWM or nonmitogen splenocytes, and antibody response to sheep RBCs.
Co-critical effect(s):	Reduced fraction of stem cells in DNA synthesis, lymphopenia, decline in the frequency of T and B lymphocytes, reduced reticulocytes, decreased number of progenitor cells, decreased RBC and WBC, suppressed ability to form antibodies.
Additivity endpoint(s):	Hematologic (blood) system, immune system
Secondary effect(s):	cystic ovaries, testicular atrophy, decreased sperm count and increased abnormal forms, increased motor activity.

Subchronic Non-Cancer Health Risk Limit (nHRL_{subchronic}) = 3 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Subchronic intake rate, L/kg/d})}$$

$$= \frac{(0.0013 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.077 \text{ L/kg-d})}$$

$$= 3.38 \text{ rounded to } \mathbf{3 \text{ µg/L}}$$

Toxicity value:	0.0013 mg/kg/day (human)
Source of toxicity value:	MDH 2007
Point of Departure:	0.013 mg/kg/day (ATSDR calculated BMCL _{0.25sd} based on route-to-route extrapolation of Lan et al., 2004 data)
Human Equivalent Dose Adjustment:	Not available
Total uncertainty factor:	10

UF allocation: 10 (intraspecies variability)
 Critical effect(s): Reduction in total WBCs, granulocytes, lymphocytes, platelets, CD4+-T cells, CD4+/CD8+ ratio, and B cells.
 Co-critical effect(s): Leukopenia.
 Additivity endpoint(s): Hematologic (blood) system and immune system.
 Secondary effect(s): anemia, lymphocytosis, thrombocytopenia, leucopenia, and leukocytosis, shorter luteal phase in females.

Chronic Non-Cancer Health Risk Limit (nHRL_{chronic}) = nHRL_{subchronic} = 3 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Chronic intake rate, L/kg/d})}$$

$$= \frac{(0.0013 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.043 \text{ L/kg-d})}$$

$$= 6.05 \text{ rounded to } 6 \text{ µg/L}$$

Toxicity value: 0.0013 mg/kg/day (human)
 Source of toxicity value: MDH 2007
 Point of Departure: 0.013 mg/kg/day (ATSDR calculated BMCL_{0.25sd} based on route-to-route extrapolation of Lan et al., 2004 data)

Human Equivalent Dose Adjustment: Not available

Total uncertainty factor: 10

UF allocation: 10 (intraspecies variability)

Critical effect(s): Reduction in total WBCs, granulocytes, lymphocytes, platelets, CD4+-T cells, CD4+/CD8+ ratio, and B cells.

Co-critical effect(s): Leukopenia.

Additivity endpoint(s): Hematologic (blood) system and immune system.

Secondary effect(s): anemia, lymphocytosis, thrombocytopenia, leucopenia, and leukocytosis, shorter luteal phase in females.

The Chronic nHRL must be protective of the subchronic exposures that occur within the chronic period and therefore, the Chronic nHRL is set equal to the Subchronic nHRL of 3 µg/L. Additivity Endpoints: Hematological (Blood) system, Immune system.

Cancer Health Risk Limit (cHRL) = 2 µg/L

$$= \frac{(\text{Additional Lifetime Cancer Risk}) \times (\text{Conversion Factor})}{[(\text{SF} \times \text{ADAF}_{<2\text{ yr}} \times \text{IR}_{<2\text{ yr}} \times 2) + (\text{SF} \times \text{ADAF}_{2-16\text{ yr}} \times \text{IR}_{2-16\text{ yr}} \times 14) + (\text{SF} \times \text{ADAF}_{16+\text{ yr}} \times \text{IR}_{16+\text{ yr}} \times 54)] / 70}$$
$$\frac{1 \times 10^{-5} \times 1000 \text{ ug/mg}}{[(0.055 \text{ (mg/kg-d)}^{-1})(10)(0.137 \text{ L/kg-d})(2) + (0.055 \text{ (mg/kg-d)}^{-1})(3)(0.047 \text{ L/kg-d})(14) + (0.055 \text{ (mg/kg-d)}^{-1})(1)(0.039 \text{ L/kg-d})(54)]/70}$$
$$= 1.89 \text{ rounded to } 2 \text{ } \mu\text{g/L}$$

Cancer classification:	A, human carcinogen
Slope factor:	0.015 to 0.055 per (mg/kg)/day (human)
Source of slope factor:	IRIS, 2000
Tumor site(s):	Leukemia

Volatile: Yes (highly volatile)

Summary of changes since 1993/1994 HRL promulgation:

MDH has implemented the method of assessing noncancer toxicity over four durations of exposure (acute, short-term, subchronic, and chronic) and assessing both cancer and noncancer endpoints simultaneously if applicable. The 1993/94 HRL (10 µg/L) is based on cancer; there was not a noncancer HRL derived at that time. Legislation passed in the 2007 regular session ([Chapter 147, Article 17, section 2](#)) established new Health Risk Limit (HRL) values, effective July 1, 2007, for chemicals when the federal standard determined by the United States Environmental Protection Agency (US EPA) is more stringent than the 1993/1994 HRL value. Maximum Contaminant Levels (MCLs) are federal standards adopted for regulation of public drinking water in Minnesota. However, MCLs incorporate a consideration of the costs required to reduce contaminant concentrations of a given level and the technological feasibility of reaching that level and therefore are not solely based on consideration of human health.

A comparison of 1993/94 HRL values to the current MCLs from the US EPA identified eleven chemicals, including benzene, that had a lower MCL value than a HRL value. The 1993/94 HRL value of 10 µg/L was revised to the MCL value of 5 µg/L as of July 1, 2007.

The noncancer HRLs (acute 10 µg/L, short-term 10 µg/L, subchronic 3 µg/L, and chronic 3 µg/L) are new. The cancer HRL (2 µg/L) is 2.5-fold lower than the 2007 MCL-based HRL and 5-fold lower than the 1993/94 cancer HRL due to: 1) utilization of more recent lifetime intake rates; 2) use of a more recent cancer risk assessment conducted by EPA; 3) application of age-dependent early-life cancer sensitivity adjustment factors; and 4) rounding to one significant digit.

Summary of toxicity testing for health effects identified in the Health Standards Statute:

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity
Tested?	Secondary Observation	Yes	Yes	Yes	Yes
Effects?	Yes ¹	Yes ²	Yes ³	Yes ⁴	Yes ⁵

Note: Even if testing for a specific health effect was not conducted for this chemical, information about that effect might be available from studies conducted for other purposes. Most chemicals have been subject to multiple studies in which researchers identify a dose where no effects were observed, and the lowest dose that caused one or more effects. A toxicity value based on the effect observed at the lowest dose across all available studies is considered protective of all other effects that occur at higher doses.

Comments on extent of testing or effects:

¹The endocrine system is not a system of particular concern and there was only a single study conducted that examined effects related to the endocrine system. This study demonstrated that women developed a significantly shorter luteal phase following inhalation exposure to benzene at low levels. Also, the urine levels of E1C before ovulation (FSH at early follicular phase and PdG in luteal phase after ovulation) in the exposed group were significantly lower than those in the internal control group. This study failed to define exposure groups and a clear dose-response relationship is unclear. The estimated oral equivalent LOAEL of this study was approximately 3-fold higher than the subchronic and chronic critical study LOAEL. These effects have been identified as secondary effects.

²Immunotoxicity effects include reduced immunoglobulin levels and a decline in lymphocyte, leukocyte, erythrocyte, and neutrophil counts as well as other immune responses. These effects have been identified as critical effects.

³Low birth weight and increased number of skeletal variants have been identified as critical acute effects. A small number of developmental inhalation studies, all by the same group of investigators, identified potential hematological effects (e.g., bimodal responses in progenitor cell counts and fluctuations in various fetal/neonatal hematological parameters) at concentrations below the acute critical study LOAEL. EPA cautioned that the hematologic effects detected should be interpreted with caution, as there were multiple limitations associated with these studies. These effects have not been identified as co-critical effects, however, a database UF was incorporated into the acute RfD derivation to address these concerns. Other effects such as stillbirth, spontaneous abortion, birth anomalies, and maternal death were effects detected at levels > 10-fold the acute critical study LOAEL.

⁴Females in occupational studies were often examined for adverse reproductive effects as a result of inhalation exposure to benzene and investigators determined that there was an increase in shortened gestation, hypermenorrhoea, hypomenorrhoea, ovarian hypoplasia, sterility, degeneration of the ovary, dysfunction of the ovary, premature interruptions of pregnancy, increased cases where the placental membrane rupture during parturition was impeded, stillbirth, and spontaneous abortions. The results of these studies must be interpreted with caution due to limitations in the study design (e.g., exposure levels) and confounding factors such as multiple chemical exposures. A reproductive inhalation study in rats reported observing testicular and ovarian lesions at estimated oral equivalent doses approximately 3-fold and > 10-fold higher than the short-term and subchronic/chronic critical study LOAELs, respectively. These effects are identified as short-term secondary effects.

⁵Levels of norepinephrine, dopamine, and serotonin were altered within various brain regions at dose levels similar to the short-term critical study LOAEL. EPA noted that although the assay had potential as a biomarker for exposure, the biological significance of these findings is questionable. Behavioral and learning disorders in mice were reported following inhalation exposure to estimated equivalent oral

doses that were > 3-fold higher than the short-term critical study LOAEL. There were, however, several limitations in the experimental procedures used in these experiments. There is a limited body of evidence indicating that benzene is neurotoxic; however, there are no human or animal studies that could be used for quantitative evaluation of potential human health risks.

References:

- Agency for Toxic Substances and Disease Registry (ATSDR). Acute Minimal Risk Levels. <http://www.atsdr.cdc.gov/mrls/index.html>
- Agency for Toxic Substances and Disease Registry (ATSDR). 2005. Draft Toxicological Profile for Benzene. <http://www.atsdr.cdc.gov/toxprofiles/tp3.pdf> (Accessed: 12/16/03 & 4/18/07)
- Aksoy M, Dincol K, Akgun T, et al. 1971. Haematological effects of chronic benzene poisoning in 217 workers. *Br J Ind Med* 28:296-302.
- Aksoy M, Dincol K, Erdem S, et al. 1972. Details of blood changes in 32 patients with pancytopenia associated with long-term exposure to benzene. *Br J Ind Med* 29:56-64.
- Aksoy M, Erdem S. 1978. Followup study on the mortality and the development of leukemia in 44 pancytopenic patients with chronic benzene exposure. *Blood* 52:285-292.
- Aksoy M, Özeris S, Sabuncu H, et al. 1987. Exposure to benzene in Turkey between 1983 and 1985: A haematological study on 231 workers. *Br J Ind Med* 44:785-787.
- Aksoy M, Erdem S, Dincol G. 1974. Leukemia in shoe-workers exposed chronically to benzene. *Blood* 44:837-841.
- Aksoy, M, Erdem, S, and Dinçol, G. 1976. Types of leukemia in chronic benzene poisoning: a study in thirty-four patients. *Acta Haematol.* 55, 65-72
- Aksoy M, Erdem S, Dinçol G, Kutlar A, Bakioğlu I, Hepyüksel T. 1984. Clinical observations showing the role of some factors in the etiology of multiple myeloma. A study in 7 patients. *Acta Haematol.* 71(2):116-20.
- American Chemistry Council Benzene, Toluene, and Xylenes VCCEP Consortium. 2006a. Voluntary Children's Chemical Evaluation Program (VCCEP) Tier 1 Pilot Submission for BENZENE (CAS No. 71-43-2) Docket Number OPPTS-00274D. <http://www.epa.gov/oppt/vccep/pubs/chem2a.htm>
- American Chemistry Council Benzene, Toluene, and Xylenes VCCEP Consortium. 2006b. Voluntary Children's Chemical Evaluation Program (VCCEP) Tier 1 Peer Consultation Report on Benzene. <http://www.epa.gov/oppt/vccep/pubs/chem2b.htm>

American Council of Governmental Industrial Hygienists (ACGIH). 2001. Documentation of the Threshold Limit Value for benzene. American Conference of Governmental Industrial Hygienists.

American Petroleum Institute. 1983. Evidence for hematotoxicity and tumorigenesis in rats exposed to 100 ppm benzene. TSCA FYI submission. OTS fiche #OTS0000241-0.

Angelosanto FA, Blackburn GR, Schreiner CA, Mackerer CR. 1996. Benzene induces a dose-responsive increase in the frequency of micronucleated cells in rat Zymbal glands. *Environ Health Perspect.* 104 Suppl 6:1331-6.

Aoyama K. 1986. Effects of benzene inhalation on lymphocyte subpopulations and immune response in mice. *Toxicol Appl Pharmacol* 85:92-101.

Axelsson et al. 1984. Exposure to solvents and outcome of pregnancy in university laboratory employees. *Br J Ind Med.* 41(3):305-12.

Baarson KA, Snyder CA, Albert RE. 1984. Repeated exposures of C57B1 mice to inhaled benzene at 10 ppm markedly depressed erythropoietic colony formation. *Toxicol Lett* 20:337-342.

Baslo A, Aksoy M. 1982. Neurological abnormalities in chronic benzene poisoning: A study of six patients with aplastic anemia and two with preleukemia. *Environ Res* 27:457-465.

Beavers JD, Himmelstein JS, Hammond SK, Smith TJ, Kenyon EM, Sweet CP. 1996. Exposure in a household using gasoline-contaminated water. *J Occup Environ Med.* 38(1):35-8.

Bergsagel DE, Wong O, Bergsagel P, et al. 1999. Benzene and multiple myeloma: appraisal of the scientific evidence. *Blood* 94(4):1174-1182.

Bloemen LJ, Youk A, Bradley TD, Bodner KM, Marsh G. 2004. Lymphohaematopoietic cancer risk among chemical workers exposed to benzene. *Occup Environ Med.* 61(3):270-4.

Bogadi-Šare A, Brumen V, Turk R, et al. 1997. Genotoxic effects in workers exposed to benzene: With special reference to exposure biomarkers and confounding factors. *Ind Health* 35:367-373.

Bogadi-Šare A, Zavalić M, Trošić I, et al. 2000. Study of some immunological parameters in workers occupationally exposed to benzene. *Int Arch Occup Environ Health* 2000:397-400.

Bogadi-Šare A, Zavalić M, Turk R. 2003. Utility of a routine medical surveillance program with benzene exposed workers. *Am J Ind Med* 44(5):467-473.

Brautbar N, Wu MP, Gabel E, Regev L. 2006. Occupational kidney cancer: exposure to industrial solvents. *Ann N Y Acad Sci.* 1076:753-64.

Brett S M, Rodricks J V, and Chinchilli V M. 1989. Review and update of leukemia risk potentially associated with occupational exposure to benzene. *Environ Health Perspect.* 82: 267–281.

Brondum, J., Shu, X. O., Steinbuch, M., Severson, R. K., Potter, J. D., & Robison, L. L. 1999. Parental cigarette smoking and the risk of acute leukemia in children. *Cancer*, 85(6), 1380-1388.

California Environmental Protection Agency. Office of Environmental Health Hazard Assessment. Public Health Goal for Benzene in Drinking Water. 2001.
<http://www.oehha.ca.gov/water/phg/pdf/BenzeneFinPHG.pdf> (Accessed:12/16/03 & 4/18/07).

California Environmental Protection Agency, Office of Environmental Health Hazard Assessment. Toxicity Criteria Database. <http://www.oehha.ca.gov/risk/ChemicalDB/index.asp> and <http://www.oehha.ca.gov/risk/pdf/cancerpotalpha81005.pdf>

Chen D, Cho SI, Chen C, et al. 2000. Exposure to benzene, occupational stress, and reduced birth weight. *Occup Environ Med* 57(10):661-667.

Chen et al. 2001. [Effects of exposure to low-level benzene and its analogues on reproductive hormone secretion in female workers]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 35(2): 83-6. [Article in Chinese]

Chen KM et al. 2005. Benzene increases protein-bound 3-nitrotyrosine in bone marrow of B6C3F1 mice. *Chem Biol Interact*. 156(2-3):81-91.

Coate WB, Hoberman AM, Durlow RS. 1984. Inhalation teratology study of benzene in rats. *Adv Mod Environ Toxicol* 6:187-198.

Cody RP, Strawderman WW, Kipen HM. 1993. Hematologic effects of benzene. Job-specific trends during the first year of employment among a cohort of benzene-exposed rubber workers. *J Occup Med* 35(8):776-782.

Collins JJ, Conner P, Friedlander BR, et al. 1991. A study of the hematologic effects of chronic low-level exposure to benzene. *J Occup Med* 33(5):619-626.

Collins JJ, Ireland B, Buckley CF, et al. 2003. Lymphohaematopoietic cancer mortality among workers with benzene exposure. *Occup Environ Med* 60(9):676-679.

Collins JJ, Ireland BK, Easterday PA, et al. 1997. Evaluation of lymphopenia among workers with low-level benzene exposure and the utility of routine data collection. *J Occup Environ Med* 39(3):232-237.

Colt, J. S., & Blair, A. 1998. Parental occupational exposures and risk of childhood cancer. *Environmental health perspectives*, 106 Suppl 3, 909-925.

Corti M, Snyder CA. 1996. Influences of gender, development, pregnancy and ethanol consumption on the hematotoxicity of inhaled 10 ppm benzene. *Arch Toxicol* 70:209-217.

Cox LA Jr. 1996. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis. *Environ Health Perspect* 104(Suppl 6):1413-1429.

Cronkite EP, Bullis JE, Inoue T, et al. 1984. Benzene inhalation produces leukemia in mice. *Toxicol Appl Pharmacol* 75:358-361.

Cronkite EP, Drew RT, Inoue T, et al. 1985. Benzene hematotoxicity and leukemogenesis. *Am J Ind Med* 7:447-456.

Cronkite EP, Drew RT, Inoue T, et al. 1989. Hematotoxicity and carcinogenicity of inhaled benzene. *Environ Health Perspect* 82:97-108.

Crump, KS. 1992. Exposure-response analyses of Pliofilm cohort. Work supported by Western States Petroleum Association, Fairfax, VA. Draft.

Crump KS. 1994. Risk of benzene-induced leukemia: A sensitivity analysis of the pliofilm cohort with additional follow-up and new exposure estimates. *J Toxicol Environ Health* 42(2):219-242.

Crump KS. 1996. Risk of benzene-induced leukemia predicted from the pliofilm cohort. *Environmental Health Perspect* 104(Suppl 6):1437-1441.

Crump KS, Allen BC. 1984. Quantitative Estimates of the Risk of Leukemia from Occupational Safety Exposures to Benzene. Final Report to the Occupational Safety and Health Administration. Ruston, LA: Science Research Systems.

Dempster AM, Evans HL, Snyder CA. 1984. The temporal relationship between behavioral and hematological effects of inhaled benzene. *Toxicol Appl Pharmacol* 76:195-203.

Dempster AM, Snyder CA. 1990. Short term benzene exposure provides a growth advantage for granulopoietic progenitor cells over erythroid progenitor cells. *Arch Toxicol* 64(7):539-544.

Dosemeci M, Rothman N, Yin SN, et al. 1997. Validation of benzene exposure assessment. *Ann N Y Acad Sci* 26(837):114-121.

Dosemeci M, Yin SN, Linet M, et al. 1996. Indirect validation of benzene exposure assessment by association with benzene poisoning. *Environ Health Perspect* 104:1343-1347.

Duarte-Davidson R, Courage C, Rushton L, Levy L. 2001. Benzene in the environment: an assessment of the potential risks to the health of the population. *Occup Environ Med*. 58(1):2-13.

Eastmond, D. A., Schuler, M., Frantz, C., Chen, H., Parks, R., Wang, L., and Hasegawa, L. 2001. Characterization and mechanisms of chromosomal alterations induced by benzene in mice and humans. *Res. Rep. Health Eff. Inst.* 103, 1–68; discussion 69–80.

Environmental Protection Agency. 1998. Carcinogenic effects of benzene: an update. Prepared by the National Center for Environmental Health, Office of Research and Development. Washington, DC. EPA/600/P-97/001F.

Environmental Protection Agency. 1999. Extrapolation of the benzene inhalation unit risk estimate to the oral route of exposure. National Center for Environmental Health, Office of Research and Development. Washington, DC. NCEA-W-0517.

Environmental Protection Agency. Health Effects Assessment Summary Tables (HEAST). 1997. Benzene.

Environmental Protection Agency. Integrated Risk Information System. Benzene. (Last revised: 4/17/2003) <http://www.epa.gov/iris/subst/0276.htm> (Last updated: 4/17/2003) (Accessed: 12/16/03 & 4/18/07).

Environmental Protection Agency. Integrated Risk Information System. Toxicological Review of Benzene (noncancer effects). (October 2002) <http://www.epa.gov/iris/toxreviews/0276-tr.pdf> (Accessed: 12/16/03 & 4/18/07).

Environmental Protection Agency. National Center for Environmental Assessment. http://cfpub.epa.gov/ncea/cfm/archive_whatsnew.cfm

Environmental Protection Agency. Office of Drinking Water. Drinking Water Standards and Health Advisories 2006. <http://www.epa.gov/waterscience/criteria/drinking/dwstandards.pdf>

Environmental Protection Agency. Office of Prevention, Pesticides, and Toxic Substances. 2007. Voluntary Children's Chemical Evaluation Program: Data Needs Assessment of Benzene. Decision on Tier 2/3 Data Needs. <http://www.epa.gov/oppt/vccep/pubs/finalbenzene.pdf>

Environmental Protection Agency Region 3. Risk Based Concentration. (click on RBC Tables PDF link) <http://www.epa.gov/reg3hwmd/risk/human/rbc/rbc1006.pdf>

Environmental Protection Agency Region 9. Preliminary Remediation Goal. (click on Region 9 PRGs 2004 Table link) <http://www.epa.gov/region09/waste/sfund/prg/files/04prgtable.pdf>

Erexson GL, Wilmer JL, Steinhagen WH, Kligerman AD. Erexson GL, Wilmer JL, Steinhagen WH, Kligerman AD. 1986. Induction of cytogenetic damage in rodents after short-term inhalation of benzene. [Environ Mutagen](#). 8(1):29-40.

Evans, HL; Dempster, AM; Snyder, CA. 1981. Behavioral changes in mice following benzene inhalation. *Neurobehav Toxicol Teratol* 3:481-485.

Exxon. 1986. Determination of maternal toxicity and fetal toxicity of benzene in rats following oral exposure. Submitted to the U.S. Environmental Protection Agency under TSCA Section 8E. OTS0536017.

Fan XH. 1992. Effect of exposure to benzene on natural killer (NK) cell activity and interleukin-2 (IL2) production of C57BL/6 mice. *J Nippon Med Sch* 59(5):393-399.

- Farris GM, Robinson SN, Gaido KW, et al. 1997a. Benzene-induced hematotoxicity and bone marrow compensation in B6C3F1 mice. *Fundam Appl Toxicol* 36(2):119-129.
- Farris GM, Robinson SN, Wong BA, et al. 1997b. Effects of benzene on splenic, thymic, and femoral lymphocytes in mice. *Toxicology* 118(2-3):137-148.
- Farris GM, Robinson SN, Gaido KW, et al. 1996a. Effects of low concentrations of benzene on mouse hematopoietic cells *in vivo*. A preliminary report. *Environ Health Perspect* 104(Suppl 6):1275-1276.
- Farris GM, Wong VA, Wong BA, et al. 1996b. Benzene-induced micronuclei in erythrocytes: An inhalation concentration-response study in B6C3F1 mice. *Mutagenesis* 11(5):455-462.
- Farris GM, Everitt JI, Irons RD, et al. 1993. Carcinogenicity of inhaled benzene in CBA mice. *Fundam Appl Toxicol* 20(4):503-507.
- Feingold, L., Savitz, D. A., & John, E. M. 1992. Use of a job-exposure matrix to evaluate parental occupation and childhood cancer. *Cancer Causes & Control : CCC*, 3(2), 161-169.
- Felix, C.A., Lange, B.J. 1999. Leukemia in infants. [Oncologist](#) 4(3): 225-240.
- Fishbeck WA, Townsend JC, Swank MG. 1978. Effect of chronic occupational exposure to measured concentrations of benzene. *J Occup Med* 20:539-542.
- Forni A. 1979. Chromosome changes and benzene exposure. A review. *Rev Environ Health*.3(1):5-17.
- Glass DC, Adams GG, Manuell RW, Bisby JA. 2000. Retrospective exposure assessment for benzene in the Australian petroleum industry . *Ann Occup Hyg*. 44(4):301-20.
- Glass DC, Gray CN, Adams GG, Manuell RW, Bisby JA. 2001. Validation of exposure estimation for benzene in the Australian petroleum industry. *Toxicol Ind Health*.17(4):113-27.
- Glass DC, Gray CN, Jolley DJ, et al. 2003. Leukemia risk associated with low-level benzene exposure. *Epidemiology* 15(5):569-577.
- Glass DC, Gray CN, Jolley DJ, Gibbons C, Sim MR. 2005. Health Watch exposure estimates: do they underestimate benzene exposure? *Chem Biol Interact*.153-154:23-32.
- Glaubiger D, von Hoff D, Holcenberg J, Kamen B, Pratt C, Ungerleider R. 1982. The relative tolerance of children and adults to anticancer drugs. *Front. Radiat. Ther. Onc.* 16:42-49.
- Goldstein BD, Snyder CA, Laskin S, Bromberg I, Albert RE, Nelson N. 1982. Myelogenous leukemia in rodents inhaling benzene. *Toxicol Lett*.13(3-4):169-73.
- Green, JK; Leong, BKJ; Laskin S. 1978. Inhaled benzene fetotoxicity in rats. *Toxicol Appl Pharmacol* 46:9-18.

Green JD, Snyder CA, LoBue J, et al. 1981a. Acute and chronic dose/response effects of inhaled benzene on multipotential hematopoietic stem (CFU-S) and granulocyte/macrophage progenitor (GMCFU-C) cells in CD-1 mice. *Toxicol Appl Pharmacol* 58:492-503.

Green JD, Snyder CA, LoBue J, et al. 1981b. Acute and chronic dose/response effect of benzene inhalation on the peripheral blood, bone marrow, and spleen cell of CD-1 male mice. *Toxicol Appl Pharmacol* 59:204-214.

Grilli S, Lutz WK, Parodi S. 1987. Possible implications from results of animal studies in human risk estimations for benzene: nonlinear dose-response relationship due to saturation of metabolism. *J Cancer Res Clin Oncol.* 113(4):349-58.

Gun RT, Pratt N, Ryan P, Roder D. 2006. Update of mortality and cancer incidence in the Australian petroleum industry cohort. *Occup Environ Med.* 63(7):476-81.

Hayes RB, Songnian Y, Dosemeci M, et al. 2001. Benzene and lymphohematopoietic malignancies in humans. *Am J Ind Med* 40(2):117-126.

Hayes RB, Yin SN, Dosemeci M, et al. 1996. Mortality among benzene-exposed workers in China. *Environ Health Perspect* 104(Suppl 6):1349-1352.

Hayes, RB, Yin SN, Dosemeci M, et al. 1997. Benzene and the dose-related incidence of hematologic neoplasms in China. *J Natl Cancer Inst* 89(14):1065-1071.

Hayes RB, Yin S, Rothman N, Dosemeci M, Li G, Travis LT, et al. 2000. Benzene and lymphohematopoietic malignancies in China. *J Toxicol Env Heal A.* 61:419-432.

Heijne et al. 2005. Toxicogenomic analysis of gene expression changes in rat liver after a 28-day oral benzene exposure. *Mutat Res.* 575(1-2):85-101.

Henderson RF. 1996. Species differences in the metabolism of benzene. *Environ Health Perspect.* 104 Suppl 6:1173-5.

Hsieh GC, Sharma RP, Parker RDR. 1988a. Subclinical effects of groundwater contaminants: I. Alteration of humoral and cellular immunity by benzene in CD-1 mice. *Arch Environ Contam Toxicol* 17:151-158.

Hsieh GC, Parker RDR, Sharma RP. 1988b. Subclinical effects of groundwater contaminants: II. Alteration of regional brain monoamine neurotransmitters by benzene in CD-1 mice. *Arch Environ Contam Toxicol* 17:799-805.

Huang, X-Y. 1991. Influence on benzene and toluene to reproductive function of female workers in leather shoe-making industry. *Chin J Prev Med* 25:89-91. [Article in Chinese]

IARC. 1987. Monograph Supplement 7 p. 120. Benzene. <http://www-cie.iarc.fr/htdocs/monographs/suppl7/benzene.html> (Accessed 11/23/04)

Infante PF, Rinsky RA, Wagoner JK, et al. 1977. Leukemia in benzene workers. *Lancet* 2:76-78.

Infante PF, White MC. 1983. Benzene: epidemiologic observations of leukemia by cell type and adverse health effects associated with low-level exposure. *Environ Health Perspect.* 52:75-82.

Infante P. 2001. Benzene: an historical perspective on the American and European occupational setting. In Gee D, Harremoes P, Keys J, MacGarvin M, Stirling A, Vaz S, Wynne B, editors. *Late lessons from early warnings: the precautionary principle 1896-2000.* Copenhagen: European Environment Agency. p 38-51.

Infante PF. 2006. The Past Suppression of Industry Knowledge of the Toxicity of Benzene to Humans and Potential Bias in Future Benzene Research. *Int J Occup Environ Health.* 12:268–272.

International Toxicity Estimates for Risk (ITER). Benzene. http://iter.ctcnet.net/publicurl/pub_view_list.cfm?crn=71%2D43%2D2 (Accessed 4/18/07)

Ireland B, Collins JJ, Buckley CF, et al. 1997. Cancer mortality among workers with benzene exposure. *Epidemiology* 8(3):318-320.

Irons, R.D., and Stillman, W.S. 1996. Impact of benzene metabolites on differentiation of bone marrow progenitor cells. *Environ Health Perspect suppl* 6: 1239-1246.

Kaatsch P, Kaletsch U, Meinert R, Miesner A, Hoisl M, Schüz J, Michaelis J. 1998. German case control study on childhood leukaemia--basic considerations, methodology and summary of the results. *Klin Padiatr* 210(4):185-91.

Kahn, H; Muzyka, V. 1973. The chronic effect of benzene on porphyrin metabolism. *Work Environ Health* 10:140-143.

Kanada M, Miyagawa M, Sato M, et al. 1994. Neurochemical profile of effects of 28 neurotoxic chemicals on the central nervous system in rats (1) effects of oral administration on brain contents of biogenic amines and metabolites. *Ind Health* 32:145-164.

Karacic V, Skender L, Bosner-Cucancic B, et al. 1995. Possible genotoxicity in low level benzene exposure. *Am J Ind Med* 27:379-388.

Keller KA, Snyder CA. 1986. Mice exposed in utero to low concentrations of benzene exhibit enduring changes in their colony forming hematopoietic cells. *Toxicology* 42:171-181.

Keller KA, Snyder CA. 1988. Mice exposed *in utero* to 20 ppm benzene exhibit altered numbers of recognizable hematopoietic cells up to seven weeks after exposure. *Fundam Appl Toxicol* 10:224-232.

- Khuder SA, Youngdale MC, Schaub EA. 1999. Assessment of complete blood count variations among workers exposed to low levels of benzene. *J Occup Environ Med* 41(9):821-826.
- Kilian, D. J., and Daniel, R. L. 1978. Cytogenetic study of workers exposed to benzene in the Texas division of Dow Chemical U.S.A. OSHA docket no. H-059, exhibit No. 230X-2, Washington, D.C.
- Kim SY, Choi JK, Cho YH, Chung EJ, Paek D, Chung HW. 2004. Chromosomal aberrations in workers exposed to low levels of benzene: association with genetic polymorphisms. *Pharmacogenetics*. 14(7):453-63.
- Kipen HM, Cody RP, Crump KS, Allen BC, Goldstein BD. 1988. Hematologic effects of benzene: a thirty-five year longitudinal study of rubber workers. *Toxicol Ind Health*. 4(4):411-30.
- Kipen HM, Cody RP, Goldstein BD. 1989. Use of longitudinal analysis of peripheral blood counts to validate historical reconstructions of benzene exposure. *Environ Health Perspect* 82:199-206.
- Kirkeleit et al. 2006. Acute suppression of serum IgM and IgA in tank workers exposed to benzene. *Scand J Immunol* 64(6):690-8.
- Knox, E. G. 1994. Leukaemia clusters in childhood: Geographical analysis in Britain. *Journal of epidemiology and community health*, 48(4), 369-376.
- Knox EG. 2005. Oil combustion and childhood cancers. *J Epidemiol Community Health*. 59(9):755-60.
- Kuna RA, Kapp RW. 1981. Embryotoxic/teratogenic potential of benzene vapor in rats. *Toxicol Appl Pharmacol* 57:1-7.
- Kuna RA, Nicolich MJ, Schroeder RE, et al. 1992. A female rat fertility study with inhaled benzene. *J Am Coll Toxicol* 11(3):275-282.
- Kwan, M. L., Buffler, P. A., Abrams, B., & Kiley, V. A. 2004. Breastfeeding and the risk of childhood leukemia: A meta-analysis. *Public health reports (Washington, D.C.: 1974)*, 119(6), 521-535.
- Lamm SH, Walters AS, Wilson R, Byrd DM, Grunwald H. 1989. Consistencies and inconsistencies underlying the quantitative assessment of leukemia risk from benzene exposure. *Environ. Health Perspect.* 82:289-297
- Lamm SH, Engel A, Byrd DM. 2005. Non-Hodgkin lymphoma and benzene exposure: a systematic literature review. *Chem Biol Interact.* 153-154:231-7.
- Lamm et al. 2006. Benzene exposure and hematotoxicity. *Science*. 312(5776): 998-9; author reply 998-9.
- Lan Q, Zhang L, Li G, et al. 2004a. Hematotoxicity in workers exposed to low levels of benzene. *Science* 306:1774-1776.

- Lan Q, Zhang L, Li G, et al. 2004b. Hematotoxicity in workers exposed to low levels of benzene: Supporting online material. *Science* 306:1774-1776.
<http://www.sciencemag.org/cgi/data/306/5702/1774/DC1/1>. August 2, 2005.
- Lan Q et al. 2005. Polymorphisms in cytokine and cellular adhesion molecule genes and susceptibility to hematotoxicity among workers exposed to benzene. *Cancer Res.* 65(20):9574-81.
- Langholz, B., Ebi, K. L., Thomas, D. C., Peters, J. M., & London, S. J. 2002. Traffic density and the risk of childhood leukemia in a los angeles case-control study. *Annals of Epidemiology*, 12(7), 482-487.
- Lee E, Im H, Oh E, Jung WW, Kang HS, Sul D. 2005. DNA Damage in T and B Lymphocytes, Bone Marrow, Splens, and Livers of Rats Exposed to Benzene. *Inhalation Toxicology*, 17:401-408.
- Li L, Sun W, Gong Z, et al. 1992. Effect of low benzene exposure on neurobehavioral function, AchE in blood and brain and bone marrow picture in mice. *Biomed Environ Sci* 5(4):349-354.
- Li G-L, Yin S-N, Watanabe T, et al. 1986. Benzene-specific increase in leukocyte alkaline phosphatase activity in rats exposed to vapors of various organic solvents. *J Toxicol Environ Health* 19:581-589.
- Li G, Yin S. 2006. Progress of epidemiological and molecular epidemiological studies on benzene in China. *Ann N Y Acad Sci.* 1076:800-9.
- Lightfoot, T. J., & Roman, E. 2004. Causes of childhood leukaemia and lymphoma. *Toxicology and applied pharmacology*, 199(2), 104-117.
- Lindstrom AB, Highsmith VR, Buckley TJ, Pate WJ, Michael LC. 1994. Gasoline-contaminated ground water as a source of residential benzene exposure: a case study. *J Expo Anal Environ Epidemiol.* 4(2):183-95.
- Lo Pumo R et al. 2006. Long-lasting neurotoxicity of prenatal benzene acute exposure in rats. *Toxicology.* 223(3):227-34.
- Maltoni C, Conti B, Cotti G. 1983. Benzene: A multipotential carcinogen: Results of long-term bioassays performed at the Bologna Institute of Oncology. *Am J Ind Med* 4:589-630.
- Maltoni, C.; Conti, B.; Scarnato, C. 1982a. Squamous cell carcinomas of the oral cavity in Sprague-Dawley rats following exposure to benzene by ingestion. First experimental demonstration. *Med. Lav.* 73(4):441-445.
- Maltoni C, Cotti G, Valgimigli L, et al. 1982b. Hepatocarcinomas in Sprague-Dawley rats following exposure to benzene by inhalation: First experimental demonstration. *Med Lav* 4:446-450.
- Marsoni, S., Ungerleider, R., Hurson, S., Simon, R., and Hammershaimb, L. 1985. Tolerance to antineoplastic agents in children and adults. *Cancer Treatment Reports* 69, 126301269.

McKinney PA, Alexandria FE, Cartwright RA, et al. 1991. Parental occupations of children with leukaemia in West Cumbria, North Humberside, and Gateshead. *Br Med J* 302(6778):681-687.

Medinsky MA, Sabourin PJ, Lucier G, Birnbaum LS, Henderson RF. 1989. A physiological model for simulation of benzene metabolism by rats and mice. *Toxicol Appl Pharmacol.* 99(2):193-206.

Mucci, L. A., Granath, F., & Cnattingius, S. 2004. Maternal smoking and childhood leukemia and lymphoma risk among 1,440,542 swedish children. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 13(9), 1528-1533.

Mukhametova, IM; Vozovaya, MA. 1972. Reproductive power and the incidence of gynecological disorders in female workers exposed to the combined effect of benzene and chlorinated hydrocarbons. *Gig Tr Prof Zabol* 16:6-9 [Article in Russian].

National Toxicology Program. 1986. Toxicology and carcinogenesis studies of benzene (CAS No. 71-43-2) in F344/N rats and B6C3F1 mice (gavage studies). Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institute of Health. National Toxicology Program—technical report series no. 289. NIH publication no. 86-2545.

Netherlands National Institute of Public Health and the Environment (RIVM). 2001. Re-evaluation of human-toxicological maximum permissible risk levels. RIVM report 711701025. Available on-line: <http://www.rivm.nl/bibliotheek/rapporten/711701025.pdf>

Ott, M. G., Tbwnsend, J. C., Fishbeck, W. A., and Langner, R. A. 1977. Mortality among individuals occupationally exposed to benzene. Submitted on behalf of Dow Chemical Co., OSHA docket no. H-059, exhibit no. 154, Washington, DC.

Parodi S, Lutz W K, Colacci A, Mazzullo M, Taningher M, and Grilli S. 1989. Results of animal studies suggest a nonlinear dose-response relationship for benzene effects. *Environ Health Perspect.* 82: 171–176.

Paustenbach DJ, Price PS, Ollison W, et al. 1992. Reevaluation of benzene exposure for the pliofilm (rubberworker) cohort (1936-1976). *J Toxicol Environ Health* 36(3):177-231.

Paustenbach DJ, Bass RD, Price P. 1993. Benzene toxicity and risk assessment, 1972-1992: implications for future regulation. *Environ Health Perspect.* 101 Suppl 6:177-200.

Pearson, R. L., Wachtel, H., & Ebi, K. L. 2000. Distance-weighted traffic density in proximity to a home is a risk factor for leukemia and other childhood cancers. *Journal of the Air & Waste Management Association* (1995), 50(2), 175-180.

Picciano D. 1979. Cytogenetic study of workers exposed to benzene. *Environ Res* 19:33-38.

- Picciano, K. J. 1980. Monitoring industrial populations by cytogenetic procedures. In: Proceedings of a Workshop on Methodology for Assessing Reproductive Hazards in the Workplace. (P. F. Infante, and M. Legator, Eds.), U.S. Government Printing Office, Washington, DC. pp. 293-306.
- Plappert U, Barthel E, Raddatz K, et al. 1994a. Early effects of benzene exposure in mice. Haematological versus genotoxic effects. *Arch Toxicol* 68:284-290.
- Pushkina, NN; Gofmekler, VA; Klevtsova, GN. 1968. Changes in content of ascorbic acid and nucleic acids produced by benzene and formaldehyde. *Bull Exp Biol Med* 66:51-53.
- Pyatt DW, Hays SM, Cushing CA. 2005. Do children have increased susceptibility for developing secondary acute myelogenous leukemia? *Chem Biol Interact.* 153-154:223-9.
- Pyatt D, Aylward L, Hays S. 2006. Is age an independent risk factor for chemically induced acute myelogenous leukemia? *Journal of Toxicology and Environmental Health, Part B*, 10(5): 379–400.
- Qu Q, Shore R, Li G, et al. 2002. Hematological changes among Chinese workers with a broad range of benzene exposures. *Am J Ind Med* 42(4):275-285.
- Raabe GK, Wong O. 1996. Leukemia mortality by cell type in petroleum workers with potential exposure to benzene. *Environ Health Perspect* 104(Suppl 6):1381-1392.
- Rappaport SM, Waidyanatha S, Qu Q, Shore R, Jin X, Cohen B, Chen LC, Melikian AA, Li G, Yin S, Yan H, Xu B, Mu R, Li Y, Zhang X, Li K. 2002. Albumin adducts of benzene oxide and 1,4-benzoquinone as measures of human benzene metabolism. *Cancer Res.* 62(5):1330-7.
- Reynolds, P., Elkin, E., Scalf, R., Von Behren, J., & Neutra, R. R. (2001). A case-control pilot study of traffic exposures and early childhood leukemia using a geographic information system. *Bioelectromagnetics*, Suppl 5, S58-68.
- Rithidech K, Au WW, Ramanujam VM, Whorton EB Jr, Legator MS. 1987. Induction of chromosome aberrations in lymphocytes of mice after subchronic exposure to benzene. *Mutat Res.* 188(2):135-40.
- Rinsky RA, Hornung RW, Landrigan PJ, et al. 1989. Re: "Benzene and leukemia: A review of the literature and a risk assessment." *Am J Epidemiol* 129:1084-1086.
- Rinsky RA, Hornung RW, Silver SR, et al. 2002. Benzene exposure and hematopoietic mortality: A long-term epidemiologic risk assessment. *Am J Ind Med* 42(6):474-480.
- Rinsky RA, Smith AB, Hornung R, et al. 1987. Benzene and leukemia: An epidemiological risk assessment. *N Eng J Med* 316:1044-1050.
- Rinsky RA, Young RJ, Smith AB. 1981. Leukemia in benzene workers. *Am J Ind Med* 2:217-245.

- Robinson SN, Shah R, Wong BA, et al. 1997. Immunotoxicological effects of benzene inhalation in male Sprague-Dawley rats. *Toxicology* 119(3):227-237.
- Rosenthal GJ, Snyder CA. 1985. Modulation of the immune response to *Listeria monocytogenes* by benzene inhalation. *Toxicol Appl Pharmacol* 80:502-510.
- Rosenthal GJ, Snyder CA. 1987. Inhaled benzene reduces aspects of cell-mediated tumor surveillance in mice. *Toxicol Appl Pharmacol* 88:35-43.
- Rothman N, Li GI, Dosemeci M, et al. 1996. Hematotoxicity among Chinese workers heavily exposed to benzene. *Am J Med* 29(3):236-246.
- Rozen MG, Snyder CA, Albert RE. 1984. Depression in B- and T-lymphocyte mitogen-induced blastogenesis in mice exposed to low concentrations of benzene. *Toxicol Lett* 20:343-349.
- Rushton L, Alderson MR 1981. An epidemiological survey of eight oil refineries in Britain. *Br.J.Ind.Med.* 38:225-234.
- Rushton L, Alderson M. 1980. The influence of occupation on health--some results from a study in the UK oil industry. *Carcinogenesis*. 1980 Sep;1(9):739-43.
- Rushton L. 1993a. A 39 year follow-up of the UK oil refinery and distribution center studies: Results for kidney cancer and leukemia. *Environmental Health Perspectives Supplements* 77-84.
- Rushton L. 1993b. Further follow-up of mortality in a United Kingdom oil distribution centre cohort. *British J. of Industrial Medicine* 50:561-569.
- Rushton L. 1996. Benzene exposure in the petroleum distribution industry associated with leukemia in the United Kingdom: Overview of the methodology of a case-control study. *Environ Health Perspect* 104(Suppl 6):1371-1374.
- Rushton L, Romaniuk H. 1997. A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom. *Occup Environ Med* 54(3):152-166.
- Savitz, DA; Whelan, EA; Kleckner, RC. 1989. Effect of parents' occupational exposures on risk of still birth, preterm delivery, and small-for-gestational-age infants. *Am J Epidemiol* 129:1201-1218.
- Savitz, D. A., & Chen, J. H. 1990. Parental occupation and childhood cancer: Review of epidemiologic studies. *Environmental Health Perspectives*, 88, 325-337.
- Schnatter AR, Armstrong TW, Thompson LS, et al. 1996. The relationship between the low-level benzene exposure and leukemia in Canadian petroleum distribution workers. *Environ Health Perspect Suppl* 104:1375-1379.

- Schnatter AR, Katz AM, Nicolich MJ, et al. 1993. A retrospective mortality study among Canadian petroleum marketing and distribution workers. *Environ Health Perspect Suppl* 101(Suppl 6):85-99.
- Seidel HJ, Barthel E, Zinser D. 1989. The hematopoietic stem cell compartments in mice during and after long-term inhalation of three doses of benzene. *Exp Hematol* 17:300-303.
- Seidenberg JM, Anderson DG, Becker RA. 1986. Validation of an in vivo developmental toxicity screen in the mouse. *Teratog Carcinog Mutagen* 6:361-374.
- Shaw G, Lavey R, Jackson R, Austin D. 1984. Association of childhood leukemia with maternal age, birth order, and paternal occupation. A case-control study. *Am J Epidemiol.* 119(5):788-95.
- Shen M, Lan Q, Zhang L, et al. 2006. Polymorphisms in genes involved in DNA double-strand break repair pathway and susceptibility to benzene-induced hematotoxicity. *Carcinogenesis* vol.27 no.10 pp.2083–2089, 2006
- Shu XO, Gao YT, Brinton LA, et al. 1988. A population based case-control study of childhood leukemia in Shanghai. *Cancer* 62:635-644.
- Shu, X. O., Stewart, P., Wen, W. Q., Han, D., Potter, J. D., Buckley, J. D., et al. 1999a. Parental occupational exposure to hydrocarbons and risk of acute lymphocytic leukemia in offspring. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 8(9), 783-791.
- Shu, X. O., Linet, M. S., Steinbuch, M., Wen, W. Q., Buckley, J. D., Neglia, J. P., et al. 1999b. Breast-feeding and risk of childhood acute leukemia. *Journal of the National Cancer Institute*, 91(20), 1765-1772.
- Smith, R.G. 1999. Benzene, NQO1, and genetic susceptibility to cancer. [Proc Natl Acad Sci U S A.](#) 96(14):7624-6.
- Smith MT, Zhang L. 1998. Biomarkers of leukemia risk: Benzene as a model. *Environ Health Perspect Suppl* 106:937-946.
- Smith AG, Worrillow LJ, Allan JM. 2007. A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. *Blood.*109(3):1233-6.
- Snyder CA, Goldstein BD, Sellakumar A. 1978. Hematotoxicity of inhaled benzene to Sprague-Dawley rats and AKR mice at 300 ppm. *J Toxicol Environ Health* 4:605-618.
- Snyder CA, Goldstein BD, Sellakumar A, et al. 1982. Toxicity of chronic benzene inhalation: CD-1 mice exposed to 300 ppm. *Bull Environ Contam Toxicol* 29:385-391.
- Snyder CA, Goldstein BD, Sellakumar AR. 1984. Evidence for hematotoxicity and tumorigenesis in rats exposed to 100 ppm benzene. *Am J Ind Med* 5:429-434.

Snyder CA, Goldstein BD, Sellakumar AR, et al. 1980. The inhalation toxicology of benzene: Incidence of hematopoietic neoplasms and hematotoxicity in AKR/J and C57BL/6J mice. *Toxicol Appl Pharmacol* 54:323-331.

Snyder CA, Sellakumar AR, James DJ, et al. 1988. The carcinogenicity of discontinuous inhaled benzene exposures in CD-1 and C57BL/6 mice. *Arch Toxicol* 62:331-335.

Sonada T, Nagata Y, Mori M, et al. 2001. Meta-analysis of multiple myeloma and benzene exposure. *J Epidemiol.* 11(6): 249-54.

Sun et al. 1992. Effect of low benzene exposure on neurobehavioral function, AChE in blood and brain and bone marrow picture in mice. *Biomed Environ Sci.* 5(4):349-54.

Surrallé's,J., Autio,K., Nylund,L., Jarventaus,H., Norppa,H., Veidebaum,T., Sorsa,M. and Peltonen,K. 1997. Molecular cytogenetic analysis of buccal cells and lymphocytes from benzene-exposed workers. *Carcinogenesis*, 18, 817–823.

Syracuse Research PhysProp Database. <http://www.syrres.com/esc/physdemo.htm>

Tatrai E, Ungvary GY, Hudak A, et al. 1980. Concentration dependence of the embryotoxic effects of benzene inhalation in CFY rats. *J Hyg Epidemiol Microbiol Immunol* 24:363-371.

Thorpe, J. J. 1974. Epidemiologic survey of leukemia in persons potentially exposed to benzene. *J. Occup. Med.* 18: 375-382.

Toft K, Olofsson T, Tunek A, et al. 1982. Toxic effects on mouse bone marrow caused by inhalation of benzene. *Arch Toxicol* 51:295-302.

Tompa A, Major J, Jakab MG. 1994. Monitoring of benzene-exposed workers for genotoxic effects of benzene: improved-working-condition-related decrease in the frequencies of chromosomal aberrations in peripheral blood lymphocytes. *Mutat Res.* 304(2):159-65.

Townsend JC, Ott MG, Fishbeck WA. 1978. Health exam findings among individuals occupationally exposed to benzene. *J Occup Med* 20:543-548.

Tsai SP, Fox EE, Ransdell JD, et al. 2004. A hematology surveillance study of petrochemical workers exposed to benzene. *Regul Toxicol Pharmacol* 40:67-73.

Tsai SP, Wen CP, Weiss NS, et al. 1983. Retrospective mortality and medical surveillance studies of workers in benzene areas of refineries. *J Occup Med* 25:685-692.

Türkel B, Egeli U. 1994. Analysis of chromosomal aberrations in shoe workers exposed long term to benzene. *Occup Environ Med.* 51(1):50-3.

- Ungvary G, Tatrai E. 1985. On the embryotoxic effects of benzene and its alkyl derivatives in mice, rats and rabbits. *Arch Toxicol Suppl* 8:425-430.
- Vacha, J; Znojil, V; Seidel, HJ; et al. 1990. Ferrokinetics and erythropoiesis in mice after long-term inhalation of benzene. *Blut* 60:41-47.
- Vara P, Kinnunen O. 1946. Benzene toxicity as a gynecologic problem. *Acta Obstet Gynecol Scand* 26:433-452.
- Vermeulen et al. 2004. Detailed exposure assessment for a molecular epidemiology study of benzene in two shoe factories in China. *Ann Occup Hyg.* 48(2):105-16.
- Wan J, Winn LM. 2006. In utero-initiated cancer: the role of reactive oxygen species. *Birth Defects Res C Embryo Today.* 78(4):326-32.
- Wang X, Chen D, Niu T, et al. 2000. Genetic susceptibility to benzene and shortened gestation: Evidence of gene-environment interaction. *Am J Epidemiol* 152(8):639-700.
- Ward CO, Kuna RA, Snyder NK, et al. 1985. Subchronic inhalation toxicity of benzene in rats and mice. *Am J Ind Med* 7:457-473.
- Ward E, Hornung R, Morris J, et al. 1996. Risk of low red or white blood cell count related to estimated benzene exposure in a rubberworker cohort (1940-1975). *Am J Ind Med* 29(3):247-257.
- Ward JB Jr, Ammenheuser MM, Ramanujam VMS, et al. 1992. The mutagenic effects of low level sub-acute inhalation exposure to benzene in CD-1 mice. *Mutat Res* 268(1):49-57.
- Wells MS, Nerland DE. 1991. Hematotoxicity and concentration-dependent conjugation of phenol in mice following inhalation exposure to benzene. *Toxicol Lett* 56(1-2):159-166.
- Wennborg et al. 2005. Congenital malformations related to maternal exposure to specific agents in biomedical research laboratories. *J Occup Environ Med.* 47(1):11-9.
- Westley-Wise VJ, Stewart BW, Kreis I, Ricci PF, Hogan A, Darling C, Corbett S, Kaldor J, Stacey NH, Warburton P. 1999. Investigation of a cluster of leukaemia in the Illawarra region of New South Wales, 1989-1996. *Med J Aust.* 171(4):178-83.
- White, KL, Jr; Lysy, HH; Munson, JA; et al. 1984. Immunosuppression of B6C3F1 female mice following subchronic exposure to benzene from drinking water. TSCA 8E Submission. OTS fiche #OTS0536214.
- Williams PR, Paustenbach DJ. 2003. Reconstruction of benzene exposure for the Pliofilm cohort (1936-1976) using Monte Carlo techniques. *J Toxicol Environ Health A.* 66(8):677-781.
- Wolf MA, Rowe VK, McCollister DD, et al. 1956. Toxicological studies of certain alkylated benzene and benzene. *AMA Arch Ind Health* 14:387-398.

Wong O. 1987a. An industry wide mortality study of chemical workers occupationally exposed to benzene: I. General results. *Br J Ind Med* 44:365-381.

Wong O. 1987b. An industry wide mortality study of chemical workers occupationally exposed to benzene: II. Dose response analyses. *Br J Ind Med* 44:382-395.

Wong O. 1995. Risk of acute myeloid leukaemia and multiple myeloma in workers exposed to benzene. *Occup Environ Med* 52:380-384.

Wong O, Raabe GK. 1995. Cell-type-specific leukemia analysis in a combined cohort of more than 208,000 petroleum workers in the United States and the United Kingdom, 1937-1989. *Regul Toxicol Pharmacol* 21:307-321.

Wong O, Raabe GK. 1997. Multiple myeloma and benzene exposure in a multinational cohort of more than 250,000 petroleum workers. *Regul Toxicol Pharmacol* 26:188-199.

Wong O, Raabe GK. 2000. Non-Hodgkin's lymphoma and exposure to benzene in a multinational cohort of more than 308,000 petroleum workers, 1937-1996. *J Occup Environ Med* 42(5):554-568.

World Health Organization. Guidelines for Drinking-Water Quality. Chapter 12 Chemical Fact Sheets. http://www.who.int/water_sanitation_health/dwq/gdwq0506_12.pdf

Xia Z-L, Xi-Peng J, Pei-Lian L, et al. 1995. Ascertainment corrected prevalence rate (ACPR) of leukopenia in workers exposed to benzene in small-scale industries calculated with capture-recapture methods. *Biomed Environ Sci* 8:30-34.

Xu X, Wiencke JK, Niu T, et al. 1998. Benzene exposure, glutathione S-transferase theta homozygous deletion, and sister chromatid exchanges. *Am J Ind Med* 33(2):157-163.

Yardley-Jones A, Anderson D, Jenkinson PC, et al. 1988. Genotoxic effects in peripheral blood and urine of workers exposed to low level benzene. *Br J Ind Med* 45:694-700.

Yardley-Jones A, Anderson D, Lovell DP, et al. 1990. Analysis of chromosomal aberrations in workers exposed to low level benzene. *Br J Ind Med* 47(1):48-51.

Yin SN, Hayes RB, Linet MS, et al. 1996a. A cohort study of cancer among benzene-exposed workers in China: Overall results. *Am J Med* 29(3):227-235.

Yin SN, Li Q, Liu Y, et al. 1987a. Occupational exposure to benzene in China. *Br J Ind Med* 44:192-195.

Yin SN, Li GL, Tain FD, et al. 1987b. Leukemia in benzene workers: A retrospective cohort study. *Br J Ind Med* 44:124-128.

Yin S, Li G, Hu Y, et al. 1987c. Symptoms and signs of workers exposed to benzene, toluene or the combination. *Ind Health* 25:113-130.

Yin SN, Hayes RB, Linet MS, et al. 1996b. An expanded cohort study of cancer among benzeneexposed workers in China. *Environ Health Perspect* 104(Suppl 6):1339-1341.

Yin SN, Li GL, Tain FD, et al. 1989. A retrospective cohort study of leukemia and other cancers in benzene workers. *Environ Health Perspect* 82:207-213.

Yin SN, Linet MS, Hayes RB, et al. 1994. Cohort study among workers exposed to benzene in China: I. General methods and resources. *Am J Ind Med* 26(3):383-400.

Zhang L, Eastmond DA, Smith MT. 2002. The nature of chromosomal aberrations detected in humans exposed to benzene. *Crit Rev Toxicol* 32(1):1-42.

Zhang LP, et al. 1996. [Investigation of health status in workers exposed to low-level benzene]. *Zhonghua Yu Yi Xue Za Zhi*. 30(3): 164-6. [Article in Chinese]

Zhang L, Rothman N, Wang Y, et al. 2000. Benzene increases aneuploidy in the lymphocytes of exposed workers: A comparison of data obtained by fluorescence in situ hybridization in interphase and metaphase cells. *Environ Mol Mutagen*. 34(4):260-8.